openPR Logo
Press release

Renal Denervation Market Globally Expected Grow Till 2020

01-16-2017 11:07 AM CET | Health & Medicine

Press release from: SA-BRC

Renal Denervation Market Globally Expected Grow Till 2020

Renal denervation is a minimally invasive catheter based procedure for treatment of resistant hypertension, a condition when at least three hypertensive drugs prove to be ineffective. Although the market experienced appreciable growth in the introductory phase, the method has been proven to be ineffective in treating resistive hypertension. Currently more clinical trials are being conducted which would decide fate of renal denervation market in the future.

Renal denervation technology was initially launched in Europe and Australia. However the study did not prove to be effective in clinical trials conducted in lucrative U.S. market. In 2014, Medtronic announced that the Symplicity trail did not meet primary and secondary end point. Symplicity renal denervation system was launched in April 2010, and is currently available in some parts of Europe, Asia, Africa and Australia. Covidien also took an exit from its clinical trials for OneShot renal denervation program. However, currently Medtronic is conducting clinical trials in U.S., U.K., Germany, Austria, Greece, Japan, and Australia. ReCor has also initiated RADIANCE -HTN study for Paradise System in patients with hypertension in the U.S. U.K., France, Germany and the Netherlands. Success in clinical trials, may fuel the renal denervation market in the future.

Free Sample Report@ http://www.sa-brc.com/Global-Renal-Denervation-Market-Assessment--Forecast-2016-2020/up57

In 2016, ReCor Medical signed a development and commercialization agreement with Otsuka Holdings, Japan. The agreement gives exclusive rights to commercialization of ReCor Paradise ultrasound based renal denervation system in Japan, China, Korea and other key Asian countries. These events indicate a positive future for renal denervation technology. Improved physician training, refined patient selection and refinement in the novel technology is expected to restore the market growth. Currently there is no treatment available for refractory hypertension patients. Regulatory clearance of renal denervation systems is therefore expected to gain rapid acceptance, considering already existing distribution channels in lucrative markets of Europe and Asia.

Click For Request TOC@ http://www.sa-brc.com/Global-Renal-Denervation-Market-Assessment--Forecast-2016-2020/upcomingdetail57

Hypertension is expected to cause over 7.5 million mortalities globally which accounts for 12.8% of the total mortalities. An article published by CNN in 2016 mentions that U.S., U.K., Canada and South Korea recorded lowest rate of hypertension globally; while Australia, China, and Russia were among the top countries with high hypertension prevalence. The data also stated that over 400 million hypertension patients were found in India and China alone. However, the level of patients diagnosed with hypertension is low in low- and middle-income countries. This data suggests that there exists enormous scope of renal denervation market development in the Asia countries.

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Renal Denervation Market Globally Expected Grow Till 2020 here

News-ID: 412801 • Views: 286

More Releases from SA-BRC

Biochip Market Analysis by Application and Trend 2017-2021
Biochips allow simultaneous testing of higher number of analytes to achieve high throughput and low cost per test. Nanotechnology has helped in miniaturization of devices to achieve higher performance standards. Microarrays are most important part of biochips which send signals to the biochip to deliver end results. Microfluidic biochips have become modern alternative to routine laboratories. Microfluidic technology which enables controlling flow of liquids in micro and pico quantities has
Acute Myeloid Leukemia Therapeutics Market Share, Analysis and Segments 2017-202 …
Acute myeloid leukemia is a cancer of blood cells and involves proliferation of abnormal blood cell types and subsequent replacement of bone marrow with cancerous cells. Major leukemia types include myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia, megakaryocytic. Treatment of leukemia mainly depends on the type of leukemia and stage. Acute myeloid leukemia therapeutics market is rich with branded as well as generic drugs classified under various classes including antineoplastic agents, corticosteroids, tyrosine
Companion Diagnostics Market Share, Trends Analysis: 2017-2021
Companion diagnostics has revolutionized cancer therapeutics and enabled physicians to select specific treatment pattern from of myriad of drugs for cancer treatment. This has improved treatment outcome manyfold and has now become and indispensable part of personalized medicine. The companion diagnostics market received great attention post success of Herceptin (trastuzumab) and Gleevec (imatinib). Rapid adoption of companion diagnostics and supportive regulatory agencies have encouraged researchers to seek molecules that target
North America and Europe Bionic Eye Market Segment Analysis And Forecast: 2017-2 …
Sudden surge in bionic eye market was experienced recently after the National Health Service (NHS) announced the sponsorship to implant bionic eyes in ten patients. The bionic eye can help regain vision in individuals with visual impairment. Although currently two bionic eye systems has received regulatory approvals, other companies in the bionic eye market are also trying to develop new technology that can help in regaining visual sense in patients. The

All 5 Releases


More Releases for Renal

Acute Renal Failure Epidemiology Insights to 2025
Publisher " Acute Renal Failure ARF Acute Kidney Injury - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Acute Renal Failure ARF Acute Kidney Injury in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Acute Renal Failure ARF Acute Kidney Injury prevalent or incident cases segmented by age, sex and subpopulations. The Report
Renal Insufficiency Market Vendor Growth Landscape 2025
Global Renal Insufficiency Market: Snapshot The demand for renal disease treatment products and therapies has been incrementing steadily in the past few years, owing to the prevalence of poor kidney functions among a vast population base across the world, especially in the Asia Pacific region, and increased government support. However, the participants of the global renal insufficiency market must take a note of weak competition among the marketed products for the
Acute Renal Failure - Pipeline Review, H1 2018
"The Report Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Acute Renal Failure Market Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)
Renal Diseases Pharmaceutical and Healthcare Analysis Information
Pune, India, 9th November 2017: WiseGuyReports announced addition of new report, titled “Frontier Pharma: Renal Diseases - High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for”. Summary The renal diseases therapy area encompasses a range of diseases of the kidney, such as chronic kidney disease (CKD), acute kidney injury, diabetic nephropathy and focal segmental glomerulosclerosis. Renal diseases are becoming increasingly common due to the
Acute Renal Failure Epidemiology Insights to 2025
Publisher " Acute Renal Failure ARF Acute Kidney Injury - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Acute Renal Failure ARF Acute Kidney Injury in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Acute Renal Failure ARF Acute Kidney Injury prevalent or incident cases segmented by age, sex and subpopulations. The Report
Renal Cluster Drug Development Pipeline Review, 2017
ReportsWorldwide has announced the addition of a new report title Renal Cluster Drug Development Pipeline Review, 2017 to its growing collection of premium market research reports. This report provides an overview of the renal cluster pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Acute Renal Failure (ARF), Kidney Transplant Rejection, and